Bayer seeks EMA approval for Aflibercept for retinal vein occlusion treatment Ruchika Sharma9 April 2025 1:41 PM ISTBerlin: Bayer has submitted an application to the European Medicines Agency (EMA) seeking approval of aflibercept 8 mg (114.3 mg/ml solution...
Visual impairment due to macular oedema: Added benefit of faricimab not proven in new study Dr. Kamal Kant Kohli31 Dec 2024 10:30 PM ISTSince July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular oedema secondary to retinal vein...
Intas Pharmaceutical gets CDSCO Panel nod to study Aflibercept Solution for Injection 40 mg/ml in Vial Dr. Divya Colin15 Dec 2024 6:00 PM ISTNew Delhi: Intas Pharmaceuticals has got approval from the Subject Expert Committee (SEC) functional Central Drug Standard Control Organisation...
Biocon Biologics forays into US Ophthalmology market with USFDA nod for Yesafili Ruchika Sharma21 May 2024 11:30 AM ISTBengaluru: Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd, today announced that the U.S....
Bayer application for regulatory approval of Aflibercept 8 mg accepted in China Ruchika Sharma26 Jan 2024 4:00 PM ISTBerlin: Bayer has announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) accepted the...
Bayer Eylea 8 mg gets Japanese marketing nod Ruchika Sharma21 Jan 2024 1:00 PM ISTBerlin: Bayer has announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted market authorization for Eylea 8 mg...
Bayer Eylea 8 mg approved in EU for treatment of two major retinal diseases Ruchika Sharma11 Jan 2024 3:30 PM ISTBerlin: Bayer has announced that the European Commission has granted marketing authorization in the European Union (EU) for new Eylea 8 mg...
Bayer Aflibercept 8 mg recommended for approval in EU Ruchika Sharma15 Nov 2023 1:00 PM ISTBerlin: Bayer has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a...
Biocon arm gets UK MHRA marketing authorisation for ophthalmic drug Yesafili Ruchika Sharma14 Nov 2023 11:29 AM ISTIt is highly similar to the reference product Eylea (aflibercept).
Biocon Biologics gets European Commission nod for critical eye treatment medicine Yesafili Ruchika Sharma21 Sept 2023 1:30 PM ISTBengaluru: Biocon Biologics Ltd., a subsidiary of Biocon Ltd., has announced that the European Commission (EC) has granted marketing authorization in...
Submit interim analysis results of study in Russia and India: CDSCO panel Tells Lupin Over Aflibercept Dr. Divya Colin28 Aug 2023 6:00 PM ISTNew Delhi: In response to the proposal to enroll an additional 298 patients from India in the study of the ophthalmic drug Aflibercept, the Subject...
Regeneron Pharma Eylea HD injection approved by USFDA for treatment of Wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy Ruchika Sharma21 Aug 2023 1:30 PM ISTTarrytown: Regeneron Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD...
